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ERBB3 interacts with EGFR and is expressed in EGFR TKI sensi-
tive NSCLC cell lines and may represent a poor prognostic marker in 
NSCLC. In this study we correlated the activity of the HDAC inhibitor 
vorinostat in NSCLC cell lines with ERBB3 expression and evaluated 
the synergistic effect of vorinostat with geﬁtinib. Further, we evaluated 
the interaction of ERBB3 and E-cadherin and their effect on response 
to geﬁtinib.
Methods: Apoptosis: cell lines were incubated in control medium or 
in the presence of various vorinostat and/or geﬁtinib concentrations 
and cell death and apoptosis were assessed using the vibrant apoptosis 
assay and evaluated with ﬂow cytometry. Samples were assessed in 
the presence or absence of geﬁtinib and/or vorinostat. Gene expres-
sion analysis was done using real-time RT-PCR and microarray gene 
expression proﬁling. Protein expression and coimmunoprecipitation 
was evaluated with western blot. 
Results: We performed detailed analysis of the apoptotic activity of 
vorinostat in a panel of 21 NSCLC cell lines. The normalized apoptotic 
to life ratio was > 2.16 in 12 cell lines (sensitive) and < 2.16 in 11 
cell lines (resistant). Using microarray analysis we found that ERBB3 
expression was signiﬁcantly higher in vorinostat sensitive compared to 
its expression in resistant cell lines (p<0.005). Vorinostat also induced 
erbB3 expression in geﬁtinib resistant cell lines. When geﬁtinib resis-
tant cell lines (IC50>10uM) were treated with vorinostat and geﬁtinib, 
synergistic effects were detected in 4 of the 5 cell lines tested. Co-
transfection of ERBB3 and E-cadherin in a geﬁtinib resistant cell line, 
H157, showed enhanced apoptotic response to geﬁtinib similar to what 
is detected in an EGFR mutant cell line H3255.
Conclusion: ERBB3 may predict response to EGFR and HDAC inhibi-
tors in NSCLC. For tumors with low ERBB3 and E-cadherin expres-
sion the combination increases expression of ERBB3 and E-cadherin 
and produce more than additive antitumor effects through increased 
apoptosis. 
PD2-3-7 Molecular Targets and Prognostic Factors, Tue, 16:00 - 17:30
The antitumor effect caused by small molecular agents targeting 
EGFR, VEGFR2 and their downstream kinases in human non 
small cell lung cancer cells
Nakachi, Ichiro1 Naoki, Katsuhiko2 Soejima, Kenzo3 Kawada, Ichiro1 
Watanabe, Hideo1 Yasuda, Hiroyuki1 Ishizaka, Akitoshi4 
1 School of Medicine, Keio University, Pulmonary Department, Shinju-
ku, Japan 2 Yokohama Municipal Citizen’s Hospital, Yokohama, Japan 3 
School of Medicine, Keio University, Pulmonary Department, Shinjuku, 
Japan 4 School of Medicine, Pulmonary Department, Keio University, 
Tokyo, Japan 
Background: Epidermal growth factor receptor-tyrosine kinase 
inhibitors (EGFR-TKI) such as geﬁtinib and erlotinib show anti-tumor 
activity in a subset of non-small cell lung cancer (NSCLC) patients 
having mutations of EGFR gene. On the other hand, clinical resistance 
to EGFR-TKI is commonly observed in spite of the initial response. 
Recent works show such resistance can be caused by a secondary 
mutation, leading to a T790M amino acid change in the EGFR tyrosine 
kinase domain. Several studies suggested the importance of VEGFR 
(Vascular endotherial growth factor receptor) and the downstream 
kinases of EGFR as potential drug targets in solid tumors.
Purpose: The aim of this study is to evaluate the efﬁcacy of alternative 
small molecules, such as AEE788, RAD001 and U0126, that inhibit 
other targets than EGFR in NSCLC cell lines with and without T790M 
mutation. AEE788 is a triple TKI for EGFR, HER2 and VEGFR2, 
while RAD001 is an inhibitor of mammalian target of rapamycin 
(mTOR), which is a serine/threonine kinase located downstream of 
PI3K-Akt pathway, and thought to have persistent activity in EGFR-
mutated cells. U0126 is an inhibitor of MEK, which is located down-
stream of Ras-Raf pathway.
Methods: We used three human NSCLC cell lines, namely, A549, 
H1650 and H1975. A549 has wild type EGFR, H1650 harbors a 
deletion mutation in exon 19 which accounts for a sensitive mutation 
to erlotinib, while H1975 possesses double mutations at L858R and 
T790M, which account for sensitiveness and resistance to erlotinib, re-
spectively. We ﬁrst treated these cells with erlotinib, AEE788, RAD001 
and U0126 as a single agent, then tried combination with either of two 
agents and evaluated the effect on cell growth as well as the phosphory-
lation of receptors and downstream kinases.
Results: AEE788 alone inhibited the cell growth more effectively than 
erlotinib alone in erlotinib-resistant cell line H1975. However it failed 
to inhibit the autophosphorylation of EGFR. While RAD001 alone 
inhibited cell growth in all these three cell lines with effective blocking 
of phosphorylation of p70S6K, which is located downstream of mTOR.
The combination of RAD001 and AEE788 resulted in more striking 
growth inhibition in H1975. This combination may work through inhib-
iting other target of AEE788, such as VEGFR, together with blocking 
PI3K pathway by RAD001.
Conclusions: EGFR downstream kinases and VEGFR will be possible 
molecular targets and double blocking of these molecules may over-
come the acquired erlotinib resistance in NSCLC.
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Background: Non-small-cell lung cancer (NSCLC) accounts for 80% 
of all lung cancers and is responsible for more deaths from cancer than 
any other tumour type in the Western world. Tumor associated macro-
phages (TAMs) constitute an important interface between tumor cells 
and the immune system and provide an environment that enhances the 
survival, proliferation and migration of tumor cells. MCP-1 chemokine 
is one of the main determinants of the macrophages content in NSCLC 
and accounts for the majority of the chemotactic activity in these 
tumors and high levels of MCP-1 correlate with poor prognosis. IL-4 
is an interleukin that displays pleiotropic immunomodulatory functions 
and is a key player in the immune reactions of the lung, involved in 
monocyte differentiation in TAM and TH2 immune responses activa-
tion. -2518 MCP-1 is a biallelic G/A polymorphism in the 5’- ﬂanking 
region of the MCP-1 gene and individuals with genotypes carrying the 
G allele produce more MCP-1 than individuals with AA genotype. The 
aim of our study was to evaluate the genetic inﬂuence of this polymor-
phism as a prognostic/predictive factor in NSCLC progression and the 
inﬂuence of a VNTR polymorphism in intron 3 of IL-4 gene in NSCLC 
progression, among -2518 MCP-1 G carrier genotypes.
Methods: DNA samples were extracted from peripheral blood cells 
of 223 consecutive patients with NSCLC. The -2518MCP-1 polymor-
phism was analyzed through PCR-RFLP (PvuII) and VNTR polymor-
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phism in intron 3 of IL-4 gene was analyzed through PCR. Analysis of 
data was performed using the computer software SPSS for windows. 
Results: A twofold increased risk for NSCLC progression (from early 
I/II stages to III/IV advanced stages of the disease) was observed for 
G carrier genotypes of -2518 MCP-1 polymorphism (P=0.028). This 
result was conﬁrmed in an age and sex adjusted multivariate logistic 
regression analysis (aOR=2.30; P=0.014). Considering the inﬂuence 
of IL-4 intron 3 polymorphism, our results do not demonstrate any 
association between -2518 MCP-1 G carrier genotypes in the risk to 
NSCLC (P=0.104). Furthermore, no statistically signiﬁcant association 
was found between IL-4 intron 3 VNTR polymorphism and NSCLC 
progression (P=0.154).
Conclusion: The preliminary results of this study indicate that the 
polymorphism -2518 MCP-1 promotes NSCLC progression, regardless 
sex and age and there is no association between IL-4 intron 3 poly-
morphism and NSCLC progression. Immunotherapy is a promising 
approach for the development of integrative therapies for cancer and 
chemokine antagonists might be useful for the treatment of cancer. The 
identiﬁcation of novel therapies designed to minimize the effects of 
MCP-1 in tumor progression should be the focus of further research.
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Background: Bronchioloalveolar carcinoma (BAC) is a subtype of 
non-small cell lung cancer (NSCLC) with distinct clinical features, 
tumor biology, response to therapy and prognosis. The disease is 
commonly multifocal, presenting as numerous nodules that are either 
conﬁned to a single lobe or distributed among several lobes of the 
lung. Primary management of multifocal BAC remains controversial 
and may include close surveillance, surgical resection and/or systemic 
therapy. Knowledge of current practice patterns and outcomes may help 
to deﬁne an optimal treatment modality. 
Methods: All patients diagnosed with pure BAC or NSCLC with BAC 
features at a major cancer center between January 2001 and Decem-
ber 2005 were identiﬁed from the hospital cancer registry and central 
pathology database. Corresponding medical records were reviewed for 
demographic parameters, disease characteristics, treatment modality 
and clinical outcomes. 
Results: In total, 109 patients with pure BAC or NSCLC with BAC 
features were identiﬁed. Twenty-four patients were excluded due to al-
ternate diagnoses, early recurrent or progressive disease, or transfer of 
care to other facilities, leaving 85 patients who were eligible for study. 
The mean age at diagnosis was 64.2 years, 54 (63.5%) were females, 
and 56 (65.9%) were smokers. At diagnosis, 22 (25.9%) were stage IA 
to IIIA and 63 (74.1%) were stage IIIB or IV. Of the 63 patients with 
multifocal BAC, 15 (23.8%) had disease conﬁned to one lobe while 48 
(76.2%) had multiple lobes involved. The primary treatment modality 
for multifocal disease included surgical resection in 49 (77.8%), sys-
temic therapy in 9 (14.2%) and observation in 5 (8.0%) cases. Among 
the 9 patients treated with systemic therapy, 6 had disease in 3 or more 
lobes, 5 received cytotoxic chemotherapy and 4 received epidermal 
growth factor receptor (EGFR) inhibitors. Median follow-up was 25.2 
months. Among the 49 patients who underwent resection, only 19 
(38.8%) developed a recurrence, most commonly in the lung (16) and 
brain (3). Recurrent or progressive disease occurred in 7/9 patients in 
the systemic therapy group and 1/5 patients in the observation group. 
Conclusions: Surgery and observation continue to be reasonable treat-
ment options for selected patients with multifocal BAC. The apparent 
lack of beneﬁt of systemic therapy in this series may reﬂect selection 
bias in referral patterns and treatment choice where only those with 
more aggressive disease (3 or more lobes involved) received cytotoxic 
agents or EGFR inhibitors. The role of systemic therapy in multifocal 
BAC deserves further prospective evaluation.
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Background: Therapies directed at both the epidermal growth factor 
receptor (EGFR) and the vascular endothelial growth factor (VEGF) 
pathways have been shown to improve survival in NSCLC. Inhibitors 
of these pathways also have radiosensitizing effects.
Methods: We are conducting a phase I/II trial incorporating B and Er 
into a strategy of I and C CbP in stage III NSCLC. Pts receive 2 cycles 
of I Cb (AUC 6), P (225 mg/m2) and B (15 mg/kg) on days 1 and 22. 
PET scans are done pre- and post-I. On day 43, pts receive weekly Cb 
(AUC 2 x 7) and P (45 mg/m2 x 7) with 74 Gy (2 Gy/d) of thoracic con-
formal radiotherapy. Cohort I (n=5) receives B at 10 mg/kg q2wks dur-
ing C therapy. Cohorts II and III (both n=5) receive the same dose of 
B as in cohort I but also receive Er at 100 mg and 150 mg po Tuesday 
- Friday of each week of C therapy, respectively. Consolidation therapy 
is then administered 3-6 weeks after completion of C therapy with Er 
(150 mg po qd) and B (15 mg/kg q3wk) for 6 cycles. Once phase I is 
complete, phase II expansion will occur. The primary endpoint is PFS 
at 1 year. All histologies are allowed including squamous.
Results: Thus far, 10 PS 0-1 pts (Cohorts I and II) have been accrued 
(med age 59 yrs, range 41-69, 6 Adeno, 4 Squamous, 7 IIIA, 3 IIIB, 3 
Never/Light smokers). All 10 pts have completed I CbP + B with one 
gr 3-4 non-hematologic toxicity (gr 3 hypertension). No pulmonary 
hemorrhage has been seen (including the 4 squamous cell pts).Thus 
far, nine have been evaluated for response (4 PR, 5 SD). In Cohort I, 
all 5 pts started C therapy on day 43 and all 5 completed therapy to 
